[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556590":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":22,"centralContacts":26,"locations":10,"responsibleParty":32,"collaborators":34,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":10,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":10,"overallStatus":62,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":10},{"fullName":5,"class":6},"University of Colorado, Denver","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Usual Care",null,"Control group to enable tracking of temporal changes in prescribing. Providers will not see any alert.",{"label":13,"type":10,"description":14,"interventionNames":15},"CDS Notification","Providers will see a clinical decision support tool within the electronic health record when treating a patient who may benefit from or is currently tapering opioid medications to encourage the provider to use a clinical care pathway that provides resources and decision support in tapering.",[16],"Other: Opioid Tapering Pathway Clinical Decision Support (CDS)",[18],{"type":6,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"Opioid Tapering Pathway Clinical Decision Support (CDS)","Clinical decision support in the form of an electronic health record (EHR)-integrated, provider facing notification suggesting the provider utilize a clinical care pathway that provides resources and decision support in opioid tapering in line with CDC guidelines.",[13],[23],{"name":24,"affiliation":5,"role":25},"Jason Hoppe, DO","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Heather Tolle, PhD","CONTACT","303-724-9924","heather.tolle@cuanschutz.edu",{"type":33,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[35,38],{"name":36,"class":37},"National Institute on Drug Abuse (NIDA)","NIH",{"name":39,"class":37},"National Institutes of Health (NIH)","100556590","evaluation-of-clinical-decision-support-in-opioid-tapering-100556590",false,"NCT06527079","Evaluation of Clinical Decision Support in Opioid Tapering","Inclusion Criteria: Primary care patients being tapered from an opioid. Tapering patients:\n\n* Have an active opioid prescription for more than 3 months and\n* Prescribed more than 90 morphine milligram equivalents (MME) per day or\n* Co-prescribed an opioid and benzodiazepine or\n* Received a reduction in opioid dosage by more than 5% MME per day\n\nExclusion Criteria:\n\n* Patients \\\u003C12 and \\>89\n* Patients with active cancer diagnosis in last 1 year\n* Patients with hospice care\u002Fpalliative care order\n* Patients with sickle cell disease diagnosis",true,"ALL","12 Years","89 Years",{"count":51,"type":52},200000,"ESTIMATED","OBSERVATIONAL","The 2022 Center for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends that when tapering a patient's opioid dose, doses should be decreased at a slow rate to reduce the risk of withdrawal symptoms, overdose, and to promote tolerance of the tapering. This project will evaluate a clinical decision support (CDS) tool in the form of a clinical care pathway that gives providers information, recommendations, and educational material on strategies for opioid tapering. Primary care providers will be randomized at the clinic location to a control arm or intervention arm. The control arm will have the clinical care pathway available, but will not be reminded of the pathway when tapering a patient. The intervention arm will receive a nudge when prescribing a tapering opioid strategy to a patient to use the clinical care pathway. The rate of opioid tapering in line with CDC guidelines will be examined as well as long-term patient outcomes of opioid overdose or poisoning using existing patient health records. The study period will be approximately 18 months.",[56,57,58,59,60,61],"Medication Abuse","Harm Reduction","Opioid Use Disorder","Opioid Prescribing","Opioid Overdose","Prevention","NOT_YET_RECRUITING","2026-04-20",{"date":65,"type":66},"2026-04-23","ACTUAL",{"date":68,"type":52},"2026-08",{"date":70,"type":52},"2027-06",{"name":5,"class":6}]